Home Retail Cipla tops drugs retail sales

    Cipla tops drugs retail sales

    By  
    SHARE

    Drug manfacturer was the top-selling drug maker in the domestic retail market for the past three months heading the chart in September pushing to second spot, market research figures showed.

    According to the market research firm ORG IMS latest figures, during September, Cipla’s sales grew 15.3 per cent from last month, garnering 4.92% in the Rs 29,000 crore domestic retail market.

    However the sales of India’s largest drug maker Ranbaxy Laboratories by revenue (including overseas sales), grew marginally 0.9 per cent with a market share of 4.81 per cent.

    Ranbaxy Laboratories had been leading the sales for the three months – June to August. is in the third position. India’s largest company by market capitalisation, Sun Pharma, is in seventh place with 3.08 per cent while Hyderabad-based Dr Reddy’s Laboratories, India’s second-largest company by revenue (including overseas sales), is in 13th spot with 2.24 per cent.

    For the nine-month period ended September, Cipla continues to maintain the top spot having pipped Ranbaxy Laboratories in May. ORG IMS figures are arrived at by collecting sales figures from around thousands of pharma retail centres across the country. The Indian domestic market is around Rs 35,000 crore and growing at 13% annually. Retail sales account for around Rs 29,000 crore while the rest comes from institutional sales.

    In the brands section, Pfizer’s multivitamin Becosules emerged as the highest selling brand in the Indian market during the September raking in Rs 1.47 crore. Last month’s highest selling cough syrup , was down -18.9 per cent from last month. Another cough syrup, Nicholas Piramal India Ltd’s Phensedyl has taken the third spot. Himalaya Herbal Healthcare’s liver tonic drug Liv 52, the only herbal drug in top 30 brands, is in the fourth position.

    For the nine-month period ended September, Novartis painkiller Voveran continues to retain the number-one spot having taken over Corex recently.